Provided by Tiger Fintech (Singapore) Pte. Ltd.

Corcept Therapeutics

70.52
+0.07000.10%
Post-market: 70.520.00000.00%16:29 EDT
Volume:626.59K
Turnover:44.04M
Market Cap:7.43B
PE:63.27
High:70.83
Open:69.50
Low:69.14
Close:70.45
Loading ...

Corcept Therapeutics options imply 3.7% move in share price post-earnings

TIPRANKS
·
06 May

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
05 May

Corcept Therapeutics (CORT): Among Billionaire Jim Simons’ RenTech’s Small-Cap Stock Picks with Huge Upside Potential

Insider Monkey
·
05 May

Corcept (CORT) To Report Earnings Tomorrow: Here Is What To Expect

StockStory
·
04 May

Corcept Therapeutics Inc expected to post earnings of 14 cents a share - Earnings Preview

Reuters
·
03 May

LIVE MARKETS-Gauging the seat grab in index musical chairs

Reuters
·
30 Apr

Corcept Therapeutics to Report Q1 Earnings: What's in the Cards?

Zacks
·
29 Apr

CORCEPT THERAPEUTICS TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS, PROVIDE CORPORATE UPDATE AND HOST CONFERENCE CALL

Business Wire
·
29 Apr

3 Healthcare Stocks That Concern Us

StockStory
·
28 Apr

Piper Sandler Reaffirms Their Buy Rating on Corcept Therapeutics (CORT)

TIPRANKS
·
25 Apr

3 Growth Companies With High Insider Ownership Achieving 70% Earnings Growth

Simply Wall St.
·
24 Apr

Is Corcept Therapeutics Incorporated (CORT) Among the Best Guru Stocks to Buy According to Wall Street Analysts?

Insider Monkey
·
24 Apr

CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025

Business Wire
·
23 Apr

BRIEF-Diabetes Care Publishes Results From Prevalence Phase Of Corcept’S CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes

Reuters
·
21 Apr

Analysts’ Top Healthcare Picks: Merus (MRUS), Corcept Therapeutics (CORT)

TIPRANKS
·
17 Apr

Corcept Therapeutics (NasdaqCM:CORT) Rises 36% in Last Quarter

Simply Wall St.
·
10 Apr

BRIEF-Corcept Initiates Trial Of Relacorilant Plus NAB-Paclitaxel And Bevacizumab

Reuters
·
07 Apr

Corcept Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer

Business Wire
·
07 Apr

Corcept Therapeutics Is Maintained at Overweight by Piper Sandler

Dow Jones
·
03 Apr

Form 4 | CORCEPT THERAPEUTICS INC Officer Joseph Douglas Lyon sold 200,650 Shares.

Filings Track
·
03 Apr